Re­lay Ther­a­peu­tics re­ports pos­i­tive PFS da­ta for its PI3Kα in­hibitor com­bo in breast can­cer

Re­lay Ther­a­peu­tics tout­ed pos­i­tive in­ter­im pro­gres­sion-free sur­vival da­ta for its PI3Kα in­hibitor in heav­i­ly treat­ed breast can­cer pa­tients.

In the ear­ly-stage Re­Dis­cov­er tri­al, Re­lay is …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER